Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the effect of escitalopram on sleep architecture utilizing a prospective design.

Hypothesis: Escitalopram will improve REM latency in patients with MDD that have responded clinically to treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder

NCT04013464

Depressive Disorder, Major

COMPLETED NA

Brain Mechanisms and Targeting Insomnia in Major Depression

NCT00628914

Major Depressive Disorder Insomnia

UNKNOWN PHASE4

The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment Depression

NCT02480400

Major Depressive Disorder

COMPLETED NA

Somatosensory Processing in Depression

NCT00386893

Depression

WITHDRAWN PHASE4

Brain Network Dynamics of Depression During Esketamine Treatment

NCT06012916

Depressive Disorder, Major

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Disturbance of sleep is a prominent symptom in depressive disorders. Alterations of sleep patterns in depressed patients include insomnia, frequent awakenings, early wake-up and non-refreshing sleep. Polysomnographic recordings have confirmed these reports, reporting reduced latency of the first REM episode of the night, with decreased density of rapid eye movements, and enhancement of total percentage of REM sleep, a reduction of deep slow wave sleep (SWS) and increase in night awakenings (Benca et al., Classification of sleep disorders).

The effects of antidepressant drugs on depression and sleep disorders, specifically SSRIs, have been thoroughly researched. The effects of escitalopram on sleep in depressed patients have been reported using a retrospective design, and in this proposed protocol, we suggest to assess the effect of escitalopram on sleep architecture utilizing a prospective design.

Hypothesis:

Escitalopram will improve REM latency in patients with MDD that have responded clinically to treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

Intervention Type DRUG

A baseline overnight polysomnography (oPSG)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients suffering from MDD, excluding a depressive episode of Bipolar Disorder.
* The depressive episode is not secondary to a general medical condition or substance abuse.
* Ages between 18-65 years old.
* Patients receiving other medications must be on a stable dosage for one month before entering the trial, including hypnotics.
* Able to understand and sign an informed consent form.

Exclusion Criteria

* Patients suffering from sleep disturbances due to a physical condition (COPD, sleep apnea or essential insomnia preceding the diagnosis of depression).
* Patients suffering from an unstable clinically significant medical condition (cardiovascular, endocrine, nutritional, hepatic, urinary).
* Patients suffering from a malignancy or neuro-degenerative such as Parkinsons' disease
* Patients suffering from a clinically significant psychiatric psychotic disease, as judged by DSM-IV criteria, such as schizophrenia or acute psychosis.
* Patients experiencing severe withdrawal symptoms following a discontinuation of hypnotic drugs, upon entry into the baseline phase.
* History of drug or alcohol dependence within the last year.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No